Recruiting
Phase 2

Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas

Sponsor:

Sidney Kimmel Cancer Center at Thomas Jefferson University

Code:

NCT03198026

Conditions

Non-Hodgkin's Lymphoma

Ann Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue

Ann Arbor Stage II Follicular Lymphoma

Ann Arbor Stage II Nodal Marginal Zone Lymphoma

Ann Abor Stage III B-Cell Non-Hodgkin Lymphoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Ibrutinib

Obinutuzumab

Laboratory Biomarker Analysis

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information